RedHill Biopharma Ltd., a specialty biopharmaceutical company with a focus on gastrointestinal and infectious diseases, boasts an impressive portfolio of drugs including Movantik, Talicia, and Aemcolo. The company's late-stage investigational development programs include RHB-204, opaganib (Yeliva), RHB-107, RHB-104, RHB-102 (Bekinda), and RHB-106. Among these is opaganib, an SK2 selective inhibitor that has completed Phase 2 studies to treat patients with SARS-CoV-2 severe COVID-19 pneumonia and is also in Phase 2 studies to treat advanced unresectable cholangiocarcinoma and prostate cancer. RedHill Biopharma Ltd. was founded in 2009 and is headquartered in Tel Aviv, Israel.